19 Result(s)

Article

Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib

Recommendations for dyslipidemia management aimed at reducing arterial occlusive events (AOEs) have been recently published. So far, no data have been reported on the management of dyslipidemia in chronic myel...

Giovanni Caocci, Olga Mulas, Isabella Capodanno… in Annals of Hematology (2021)

Article

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Hypertension is a commonly reported comorbidity in patients diagnosed with chronic myeloid leukemia (CML), and its management represents a challenge in patients treated with 2nd- or 3rd-generation tyrosine kin...

Olga Mulas, Giovanni Caocci, Fabio Stagno, Massimiliano Bonifacio… in Annals of Hematology (2020)

Article

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter ...

Fabio Efficace, Fabio Stagno, Alessandra Iurlo, Massimo Breccia… in Leukemia (2020)

Article

Efficacy and safety of bosutinib in chronic phase CML patients develo** pleural effusion under dasatinib therapy

Mario Tiribelli, Elisabetta Abruzzese, Isabella Capodanno… in Annals of Hematology (2019)

Article

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians’ judgement. However, dat...

Monica Crugnola, Fausto Castagnetti, Massimo Breccia, Dario Ferrero… in Annals of Hematology (2019)

Article

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML pa...

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo… in Annals of Hematology (2019)

Article

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocyto...

Massimo Breccia, Luigiana Luciano, Novella Pugliese, Elena Rossi… in Annals of Hematology (2019)

Article

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. W...

Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio… in Annals of Hematology (2019)

Article

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a D...

Alessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese… in Annals of Hematology (2018)

Article

EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations

Massimiliano Bonifacio, Gianni Binotto, Elisabetta Calistri… in Annals of Hematology (2014)

Article

Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enr...

Roberto Latagliata, Dario Ferrero, Alessandra Iurlo, Francesco Cavazzini… in Drugs & Aging (2013)